NKTR Investor Alert: Nektar Therapeutics Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Allegedly Concealing Known Trial Defects: SueWallSt
The Red Flags: What Insiders Allegedly Knew Before Shareholders Did
NEW YORK, April 23, 2026 /PRNewswire/ -- SueWallSt announces that a securities class action has been filed against Nektar Therapeutics (NASDAQ: NKTR).
YOU MAY BE AFFECTED IF YOU:
Submit your information to recover losses or contact Joseph E. Levi, Esq. at [email protected] or (888) SueWallSt.
Nektar shares fell $4.14 per share, or 7.77%, closing at $49.16 on December 16, 2025 after the Company disclosed that four ineligible patients had been enrolled in its pivotal REZOLVE-AA Phase 2b trial, causing the primary endpoint to miss statistical significance.
What They Allegedly Knew
The securities action alleges that throughout a ten-month Class Period, Nektar's senior leadership repeatedly assured investors that enrollment in the REZOLVE-AA trial followed strict protocol standards and eligibility criteria. These assurances were made across multiple earnings calls, SEC filings, and press releases from February through November 2025. Yet on December 16, 2025, when topline results were announced, the Company admitted that four patients had "major study eligibility violations that should have disqualified them for randomization into the trial."
The lawsuit contends this was not a surprise to insiders. Rezpegaldesleukin was Nektar's lead product candidate, and executives' 2024 annual bonuses were tied directly to maintaining enrollment timelines for the REZOLVE-AA trial.
The Red Flags That Emerged
Inside Knowledge vs. Public Statements
As plaintiffs assert, the gap between what was said publicly and what was allegedly known internally is central to this case. On every quarterly earnings call during the Class Period, the Company's Chief Research and Development Officer detailed the enrollment criteria, including SALT score thresholds, six-month disease stability requirements, and washout periods. The complaint charges that these repeated, specific assurances about protocol compliance were made while enrollment violations had already occurred or were known to have occurred.
Multiple analyst firms, including Piper Sandler, BTIG, Jefferies, Oppenheimer, H.C. Wainwright, William Blair, and Citi, attributed the December 16 stock decline specifically to the revelation of the four ineligible patients.
"The timeline raises important questions about when certain risks were known internally versus when they were disclosed to the investing public. Investors who purchased shares in reliance on repeated assurances about trial protocol compliance deserve answers." -- Joseph E. Levi, Esq.
Act now to protect your rights or call Joseph E. Levi, Esq. at (212) 363-7500.
ABOUT THE FIRM -- Levi & Korsinsky represents investors in securities class actions nationwide, with a track record of recovering hundreds of millions for shareholders harmed by alleged corporate concealment. Ranked among ISS Top 50 for seven consecutive years. Lead plaintiff applications must be submitted by May 5, 2026.
CONTACT:
SueWallSt
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
[email protected]
Tel: (888) SueWallSt
Fax: (212) 363-7171
SOURCE SueWallSt.com